**Shock - Pipeline Review, H2 2011**

**Description:**  
Shock - Pipeline Review, H2 2011

**Summary**

Global Markets Direct's, 'Shock - Pipeline Review, H2 2011', provides an overview of the Shock therapeutic pipeline. This report provides information on the therapeutic development for Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shock. 'Shock - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

**Scope**

- A snapshot of the global therapeutic scenario for Shock.
- A review of the Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Shock pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

**Reasons to buy**

- Identify and understand important and diverse types of therapeutics under development for Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Shock pipeline depth and focus of Shock therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

**Keywords**

Shock Therapeutic Products under Development, Key Players in Shock Therapeutics, Shock Pipeline Overview, Shock Pipeline, Shock Pipeline Assessment

**Contents:**

List of Tables  
List of Figures  
Introduction  
Global Markets Direct Report Coverage  
Shock Overview
Therapeutics Development
An Overview of Pipeline Products for Shock
Shock Therapeutics under Development by Companies
Shock Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Shock Therapeutics - Products under Development by Companies
Shock Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Shock Therapeutics Development
Baxter International Inc.
Medinox, Inc.
AstraZeneca PLC
Athersys, Inc.
Green Cross Corporation
Curacyte AG
Novimmune SA
Atox Bio Inc.
Ferring Pharmaceuticals, Inc.
Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CytoFab - Drug Profile
MultiStem - Drug Profile
NI-0101 - Drug Profile
Hemoximer - Drug Profile
Hemoximer - Drug Profile
Norathiol - Drug Profile
Thiamine - Drug Profile
Albumin - Drug Profile
Premarin - Drug Profile
Norepinephrine + Dobutamine - Drug Profile
Epinephrine - Drug Profile
Methylene Blue + Nitric Oxide - Drug Profile
Hydrocortisone - Drug Profile
Terlipressin - Drug Profile
Arginine Vasopressin - Drug Profile
Recombinant Human Activated Protein C - Drug Profile
Hydrocortisone + Fludrocortisone - Drug Profile
Recombinant Human Activated Protein C + Hydrocortisone + Fludrocortisone - Drug Profile
Dopamine - Drug Profile
Norepinephrine - Drug Profile
Dopamine - Drug Profile
Norepinephrine - Drug Profile
Recombinant Human Insulin + Hydrocortisone + Fludrocortisone - Drug Profile
Recombinant Human Insulin + Hydrocortisone - Drug Profile
Phenylepinephrine - Drug Profile
Acetyl-L-Carnitine - Drug Profile
AB103 - Drug Profile
L-Carnitine - Drug Profile
GIK - Drug Profile
Terlipressin + Dopamine + Norepinephrine - Drug Profile
Pyruvate - Drug Profile
Glutamine - Drug Profile
GM-CSF - Drug Profile
Simvastatin - Drug Profile
MIF Inhibitors - Drug Profile
Heparin - Drug Profile
Hydrocortisone - Drug Profile
Levosimendan + Nitric Oxide - Drug Profile
Phenylephrine - Drug Profile
Hydrocortisone - Drug Profile
Hypertonic Saline + Terlipressin - Drug Profile
Tetraspan - Drug Profile
Anti-MIF Antibody - Drug Profile
Ipoxyn - Drug Profile
I.V.-Globulin S inj. - Drug Profile
AP-1100 - Drug Profile
Shock Therapeutics – Drug Profile Updates
Shock Therapeutics - Discontinued Products
Shock - Featured News
Jul 28, 2011: Boston Therapeutics To Present Data On Ipoxyn At Symposium At Massachusetts General Hospital
Mar 28, 2011: PHOENIX Phase III Trial Of PHP For Distributive Shock To Continue After Positive Midpoint Recommendation From DMB
Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting
Jun 05, 2009: Curacyte Reports Enrollment Of First Patient In The PHOENIX Trial For The Drug Hemoximer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Shock, H2 2011
Products under Development for Shock – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Baxter International Inc., H2 2011
Medinox, Inc., H2 2011
AstraZeneca PLC, H2 2011
Athersys, Inc., H2 2011
Green Cross Corporation, H2 2011
Curacyte AG, H2 2011
Novimmune SA, H2 2011
Atox Bio Inc., H2 2011
Ferring Pharmaceuticals, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Shock Therapeutics – Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Shock, H2 2011
Products under Development for Shock – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/1964214/](http://www.researchandmarkets.com/reports/1964214/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Shock - Pipeline Review, H2 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/1964214/">http://www.researchandmarkets.com/reports/1964214/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2SIBJ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World